78816

PET Imaging, Whole Body, with Concurrent CT for Localization and Attenuation Correction

CPT code 78816 represents Positron Emission Tomography (PET) whole body imaging performed with concurrent computed tomography (CT) for anatomical localization and attenuation correction. This advanced diagnostic imaging technique is widely used in oncology, cardiology, and neurology to evaluate metabolic activity within tissues. The procedure involves the administration of a radioactive tracer, most commonly Fluorodeoxyglucose F-18 (FDG), which is a glucose analog. Cancer cells, being highly metabolically active, typically exhibit increased glucose uptake, leading to higher accumulation of FDG, making them visible on the PET scan. The patient is typically instructed to fast for several hours prior to the study to optimize tracer uptake and minimize physiological uptake in non-target tissues. After tracer injection, there is an uptake phase, usually lasting 45-90 minutes, during which the tracer distributes throughout the body. During this time, the patient rests quietly to minimize muscle uptake. Following the uptake phase, the patient is positioned on the PET/CT scanner bed. The scanner then acquires both a diagnostic quality CT scan and a PET emission scan simultaneously or sequentially in the same setting. The CT component provides detailed anatomical information, which is crucial for precisely locating areas of increased metabolic activity detected by the PET scan. It also provides data for attenuation correction, improving the quantitative accuracy of the PET images. The combined PET/CT images are then reconstructed, offering fused images that superimpose the metabolic information from PET onto the anatomical context of CT, enabling clinicians to identify and characterize lesions more accurately than either modality alone. This comprehensive approach is particularly valuable for cancer diagnosis, staging, restaging, treatment response assessment, and surveillance.

Clinical Indications

  • Diagnosis and staging of various cancers (e.g., lung, colorectal, lymphoma, melanoma, head and neck, esophageal, breast cancer)
  • Restaging of cancer after treatment or during surveillance for recurrence
  • Assessment of therapeutic response to chemotherapy or radiation therapy
  • Differentiation between benign and malignant lesions, especially in indeterminate masses (e.g., solitary pulmonary nodule)
  • Identification of unknown primary cancer site in patients with metastatic disease
  • Evaluation of cardiac viability in ischemic heart disease (e.g., to guide revascularization procedures)
  • Localization of seizure foci in epilepsy patients
  • Assessment of dementia, particularly to differentiate Alzheimer's disease from other forms of dementia
  • Monitoring for infection or inflammation in specific cases where traditional imaging is inconclusive
  • Guiding biopsy procedures to metabolically active areas

Procedure Steps

  1. Patient preparation: Review patient history, explain procedure, verify fasting status (typically 4-6 hours), and check blood glucose levels.
  2. Radiopharmaceutical administration: Intravenous injection of the appropriate PET tracer (e.g., F-18 FDG).
  3. Uptake phase: Patient rests quietly in a warm room for 45-90 minutes to allow tracer distribution and uptake in target tissues.
  4. Patient positioning: Patient is positioned supine on the PET/CT scanner bed, often with arms above the head for optimal image acquisition.
  5. CT acquisition: A diagnostic quality CT scan is performed over the designated anatomical region (e.g., whole body from skull base to mid-thigh).
  6. PET emission acquisition: Immediately following or concurrent with the CT, the PET scanner acquires emission data over the same anatomical region.
  7. Image reconstruction: Raw data from both PET and CT are processed and reconstructed into fused images, incorporating CT-based attenuation correction.
  8. Image review and interpretation: A nuclear medicine physician or radiologist interprets the fused PET/CT images, generating a diagnostic report.

Coding Guidelines

  • CPT code 78816 specifically describes PET whole body imaging with concurrent CT for localization and attenuation correction. This code should be used when both PET emission and CT localization/attenuation correction data are acquired in the same session.
  • Diagnostic CT is included in 78816 when performed concurrently for anatomical localization and attenuation correction. Separate coding for the CT component (e.g., 74176, 74177, 74178) is generally not appropriate unless a separate, independent diagnostic CT study is performed for a distinct indication and interpreted separately.
  • The radiopharmaceutical (e.g., A9552 for F-18 FDG) should be billed separately in addition to 78816.
  • Oral and/or intravenous contrast for the CT component may be billed separately with appropriate contrast administration codes (e.g., 96374 for IV administration, A9576 for oral contrast, Q9967/Q9968 for IV contrast), if medically necessary for a diagnostic-quality CT and not simply for attenuation correction.
  • Medicare's National Coverage Determination (NCD) for PET scans outlines specific covered indications for various types of cancer and other conditions. Coverage can vary by payer, so verification of medical necessity and coverage policies is crucial.
  • When a PET scan is performed without a concurrent CT (e.g., using a dedicated PET scanner or non-diagnostic CT for attenuation), different CPT codes (e.g., 78811-78815) would apply.
  • For brain PET scans, specific codes like 78608 or 78814 (with concurrent CT) should be used, not 78816, as 78816 implies 'whole body'.

Associated ICD-10 Codes